查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1869948

僵直性脊椎炎市场规模、份额和趋势分析报告：按药物类别、分销管道、地区和细分市场预测（2025-2033 年）

Ankylosing Spondylitis Market Size, Share & Trends Analysis Report By Drug Class (NSAID, TNF Inhibitors), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

僵直性脊椎炎市场摘要

2024年全球僵直性脊椎炎市场规模估计为62.9亿美元，预计2033年将达到110.8亿美元。

预计从 2025 年到 2033 年，该市场将以 6.4% 的复合年增长率成长。推动市场成长的因素包括发炎性疾病盛行率的上升以及医疗保健提供者诊断意识的提高。

由于发炎性疾病盛行率不断上升以及医疗保健提供者诊断意识的增强，市场持续成长。僵直性脊椎炎 (AS)相关的慢性下背痛可藉助磁振造影 (MRI) 和电脑电脑断层扫描)等先进影像技术在早期阶段得到准确诊断，从而增加了对早期疗育的需求。这有助于加快治疗启动并改善长期疗效，进而推动标靶治疗的应用。例如，根据《美国管理式医疗杂誌》(American Journal of Managed Care) 2024 年 9 月的一份报告，美国食品药物管理局(FDA) 已批准 bimekizumab-bkzx (Bimzelx) 用于治疗成人僵直性脊椎炎(AS)、非关节炎性中轴型脊椎干癣性关节炎(Pax-A)。这核准首个核准用于这些适应症的 IL-17A 和 IL-17F 双重抑制剂。基于 III 期 BE MOBILE 试验的结果，这项里程碑式的核准扩大了治疗选择范围，并加强了市场成长。

生物製药的进步也是推动市场成长的主要因素。标靶肿瘤坏死因子 (TNF) 和白细胞介素-17 (IL-17) 路径的生物製药彻底改变了僵直性脊椎炎的治疗。这些治疗方法因其能够减轻发炎、延缓疾病进展并改善生活质量，而成为医生和患者的首选。例如，UCB 在 2023 年 11 月举行的 ACR Convergence 2023 大会上宣布，BIMZELX（bimekizumab）在五年内持续改善了疾病活动度、身体功能和生活质量，且安全性良好。在开放标籤扩展研究 (OLE) 中入组的 303 名患者中，有 202 名患者持续接受治疗至第 256 週，ASAS40 缓解率维持在约 50%。生物相似药的推出有望提高治疗的可近性和成本效益，从而进一步扩大治疗应用范围。製药公司正积极投资临床研究，以开发新型生物製药和小分子疗法。增加新药认证，可以提供病人和医生更多选择。

对个人化医疗的日益重视正在塑造市场未来的机会。基因检测和基于生物标记的方法能够更精准地选择适合个别患者的治疗方法。这些方法提高了治疗效果，并降低了副作用的风险。数位健康平台和远端医疗的扩展正在改善患者监测，并提高患者对长期治疗方案的依从性。製药公司和研究机构之间日益密切的合作正在加速创新治疗方法的研发。僵直性脊椎炎造成的全球性残疾负担也推动了对先进治疗方法的需求，以恢復患者的活动能力并减轻疼痛。预计这些趋势将在未来几年内持续推动市场成长。

目录

第一章调查方法和范围

第二章执行摘要

第三章僵直性脊椎炎市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章僵直性脊椎炎市场：药物类别业务分析

  • 2024 年及 2033 年各药物类别市占率
  • 药物类别细分仪表板
  • 按药物类别分類的市场规模、预测和趋势分析，2021-2033年
  • 非类固醇消炎剂（NSAIDs）
  • TNF抑制剂
  • 其他药物类别

第五章僵直性脊椎炎市场：通路的业务分析

  • 2024 年及 2033 年分销通路市场份额
  • 分销通路细分仪表板
  • 按分销管道分類的市场规模、预测和趋势分析，2021-2033年
  • 医院药房
  • 零售药房
  • 其他的

第六章僵直性脊椎炎市场：区域估算与趋势分析

  • 2024 年及 2033 年区域市占率分析
  • 区域市场概览
  • 市场规模及预测趋势分析（2021-2033）：
  • 北美洲
    • 按国家/地区划分，2021-2033 年
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争情势

  • 参与企业概况
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介
    • AbbiVie, Inc.
    • Amgen, Inc.
    • Pfizer, Inc.
    • Johnson &Johnson, Inc.
    • Novartis AG
    • UCB, Inc.
    • Eli Lilly and Company
    • Merck &Co., Inc.
    • Zydus Lifescience Ltd.
    • Izana Bioscience
Product Code: GVR-4-68038-728-5

Ankylosing Spondylitis Market Summary

The global ankylosing spondylitis market size was estimated at USD 6.29 billion in 2024 and is projected to reach USD 11.08 billion by 2033, growing at a CAGR of 6.4% from 2025 to 2033. The market is growing due to the rising prevalence of inflammatory diseases and greater diagnostic awareness among healthcare providers.

The market is growing due to the rising prevalence of inflammatory diseases and greater diagnostic awareness among healthcare providers. Chronic back pain associated with ankylosing spondylitis is increasing demand for early intervention, supported by advanced imaging techniques such as MRI and CT scans that enable accurate diagnosis at earlier stages. This accelerates treatment initiation and improves long-term outcomes, driving adoption of targeted therapies. For instance, in September 2024, the American Journal of Managed Care reported that the FDA had approved bimekizumab-bkzx (Bimzelx) for adults with AS, nr-axSpA, and PsA, marking the first dual IL-17A and IL-17F inhibitor to secure approval for these indications. Supported by Phase 3 BE MOBILE trials, this milestone expanded therapeutic options and strengthened market growth.

Advancements in biologic therapies are another major factor contributing to market growth. Biologic agents targeting tumor necrosis factor (TNF) and interleukin-17 (IL-17) pathways have transformed the management of ankylosing spondylitis. These therapies reduce inflammation, slow disease progression, and improve quality of life, making them the preferred choice among physicians and patients. For instance, in November 2023, UCB reported at ACR Convergence 2023 that BIMZELX (bimekizumab) delivered sustained five-year improvements in ankylosing spondylitis across disease activity, physical function, and quality of life, with consistent safety. Among 303 patients entering OLE, 202 remained at Week 256, with ASAS40 response rates maintained near 50%. The introduction of biosimilars is also increasing accessibility and affordability, which further expands treatment adoption rates. Pharmaceutical companies actively invest in clinical research to develop novel biologics and small-molecule therapies. Regulatory bodies ' increasing approvals of new drugs give patients and physicians more options.

The rising focus on personalized medicine shapes future opportunities in the market. Genetic testing and biomarker-driven approaches enable more precise selection of therapies tailored to individual patient needs. Such approaches enhance treatment effectiveness and reduce the risk of adverse reactions. The expansion of digital health platforms and telemedicine is improving patient monitoring and adherence to long-term treatment plans. Growing collaborations between pharmaceutical companies and research institutes lead to faster development of innovative treatment options. The global burden of disability linked with ankylosing spondylitis is also pushing demand for advanced therapies that restore mobility and reduce pain. These trends are expected to sustain market growth over the coming years.

Global Ankylosing Spondylitis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global ankylosing spondylitis market report based on drug class, distribution channel, and region:

  • Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
  • Non-Steroidal Anti-Inflammatory Drug (NSAID)
  • TNF Inhibitors
    • Humira
    • Simponi
    • Remicade
    • Enbrel
    • Cimzia
    • Other TNF Inhibitors
  • Other Drug Classes
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacy
  • Retail Pharmacy
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Distribution channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Ankylosing Spondylitis Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Ankylosing Spondylitis Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2033
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
  • 4.4. Non-Steroidal Anti-Inflammatory Drug (NSAID)
    • 4.4.1. Non-Steroidal Anti-Inflammatory Drug (NSAID) Market, 2021 - 2033 (USD Million)
  • 4.5. TNF Inhibitors
    • 4.5.1. TNF Inhibitors Market, 2021 - 2033 (USD Million)
    • 4.5.2. Humira
      • 4.5.2.1. Humira Market, 2021 - 2033 (USD Million)
    • 4.5.3. Simponi
      • 4.5.3.1. Simponi Market, 2021 - 2033 (USD Million)
    • 4.5.4. Remicade
      • 4.5.4.1. Remicade Market, 2021 - 2033 (USD Million)
    • 4.5.5. Enbrel
      • 4.5.5.1. Enbrel Market, 2021 - 2033 (USD Million)
    • 4.5.6. Cimzia
      • 4.5.6.1. Cimzia Market, 2021 - 2033 (USD Million)
    • 4.5.7. Other TNF Inhibitors
      • 4.5.7.1. Other TNF Inhibitors Market, 2021 - 2033 (USD Million)
  • 4.6. Other Drug Classes
    • 4.6.1. Other Drug Classes Market, 2021 - 2033 (USD Million)

Chapter 5. Ankylosing Spondylitis Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2033
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 5.4. Hospital Pharmacy
    • 5.4.1. Hospital Pharmacy Market, 2021 - 2033 (USD Million)
  • 5.5. Retail Pharmacy
    • 5.5.1. Retail Pharmacy Market, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Ankylosing Spondylitis Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Ankylosing Spondylitis Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. UK Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Brazil Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. Argentina Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. AbbiVie, Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Amgen, Inc.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Pfizer, Inc.
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Johnson & Johnson, Inc.
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Novartis AG
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. UCB, Inc.
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Eli Lilly and Company
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Merck & Co., Inc.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Zydus Lifescience Ltd.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Izana Bioscience
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global ankylosing spondylitis market, by region, 2021 - 2033 (USD Million)
  • Table 4. Global ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 5. Global ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 6. North America ankylosing spondylitis market, by country, 2021 - 2033 (USD Million)
  • Table 7. North America ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 8. North America ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 9. U.S. ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 10. U.S. ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11. Canada ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 12. Canada ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 13. Mexico ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 14. Mexico ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 15. Europe ankylosing spondylitis market, by country, 2021 - 2033 (USD Million)
  • Table 16. Europe ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 17. Europe ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 18. UK ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 19. UK ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20. Germany ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 21. Germany ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 22. France ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 23. France ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24. Italy ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 25. Italy ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 26. Spain ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 27. Spain ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 28. Norway ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 29. Norway ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30. Denmark ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 31. Denmark ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 32. Sweden ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 33. Sweden ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 34. Asia Pacific ankylosing spondylitis market, by country, 2021 - 2033 (USD Million)
  • Table 35. Asia Pacific ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 36. Asia Pacific ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD
  • Table 37. Japan ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 38. Japan ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39. China ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 40. China ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 41. India ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 42. India ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 43. Australia ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 44. Australia ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45. South Korea ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 46. South Korea ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 47. Thailand ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 48. Thailand ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 49. Latin America ankylosing spondylitis market, by country, 2021 - 2033 (USD Million)
  • Table 50. Latin America ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 51. Latin America ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52. Brazil ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 53. Brazil ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 54. Argentina ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 55. Argentina ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 56. Middle East & Africa Ankylosing spondylitis market, by country, 2021 - 2033 (USD Million)
  • Table 57. Middle East & Africa ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 58. Middle East & Africa ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 59. South Africa ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 60. South Africa ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61. Saudi Arabia ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 62. Saudi Arabia ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 63. UAE ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 64. UAE ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 65. Kuwait ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 66. Kuwait ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Ankylosing spondylitis market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and drug class outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Ankylosing spondylitis market dynamics
  • Fig. 12 Ankylosing spondylitis market: Porter's five forces analysis
  • Fig. 13 Ankylosing spondylitis market: PESTLE analysis
  • Fig. 14 Drug Class market, 2021 - 2033 (USD Million)
  • Fig. 15 Non-Steroidal Anti-Inflammatory Drug (NSAID) market, 2021 - 2033 (USD Million)
  • Fig. 16 TNF Inhibitors market, 2021 - 2033 (USD Million)
  • Fig. 17 Humira market, 2021 - 2033 (USD Million)
  • Fig. 18 Simponi market, 2021 - 2033 (USD Million)
  • Fig. 19 Remicade market, 2021 - 2033 (USD Million)
  • Fig. 20 Enbrel market, 2021 - 2033 (USD Million)
  • Fig. 21 Cimzia market, 2021 - 2033 (USD Million)
  • Fig. 22 Other TNF Inhibitors market, 2021 - 2033 (USD Million)
  • Fig. 23 Other Drug Classes market, 2021 - 2033 (USD Million)
  • Fig. 24 Distribution channel market, 2021 - 2033 (USD Million)
  • Fig. 25 Hospital Pharmacy market, 2021 - 2033 (USD Million)
  • Fig. 26 Retail Pharmacy market, 2021 - 2033 (USD Million)
  • Fig. 27 Others market, 2021 - 2033 (USD Million)
  • Fig. 28 Ankylosing spondylitis market revenue, by region
  • Fig. 29 Regional marketplace: Key takeaways
  • Fig. 30 North America ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 31 U.S. country dynamics
  • Fig. 32 U.S. ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 33 Canada country dynamics
  • Fig. 34 Canada ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 35 Mexico country dynamics
  • Fig. 36 Mexico ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 37 Europe ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 38 UK country dynamics
  • Fig. 39 UK ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 40 Germany country dynamics
  • Fig. 41 Germany ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 42 France country dynamics
  • Fig. 43 France ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 44 Italy country dynamics
  • Fig. 45 Italy ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 46 Spain country dynamics
  • Fig. 47 Spain ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 48 Norway country dynamics
  • Fig. 49 Norway ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 50 Sweden country dynamics
  • Fig. 51 Sweden ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 52 Denmark country dynamics
  • Fig. 53 Denmark ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 54 Asia Pacific ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 55 Japan country dynamics
  • Fig. 56 Japan ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 57 China country dynamics
  • Fig. 58 China ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 59 India country dynamics
  • Fig. 60 India ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 61 Australia country dynamics
  • Fig. 62 Australia ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 63 South Korea country dynamics
  • Fig. 64 South Korea ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 65 Thailand country dynamics
  • Fig. 66 Thailand ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 67 Latin America ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 68 Brazil country dynamics
  • Fig. 69 Brazil ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 70 Argentina country dynamics
  • Fig. 71 Argentina ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 72 MEA ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 73 South Africa country dynamics
  • Fig. 74 South Africa ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 75 Saudi Arabia country dynamics
  • Fig. 76 Saudi Arabia ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 77 UAE country dynamics
  • Fig. 78 UAE ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 79 Kuwait country dynamics
  • Fig. 80 Kuwait ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 81 Company categorization
  • Fig. 82 Company market position analysis
  • Fig. 83 Strategic framework